ABO2102, a Multivalent KRAS-Targeting mRNA Therapeutic Cancer Vaccine by Abogen Biosciences, Achieves IND Approval in Both China and the U.S.

Aug 04, 2025 21:45 CST Updated 21:45

Abogen

Nucleic Acid Drug Developer

On August 4, 2025, according to the official website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration, Abogen's self-developed novel mRNA cancer vaccine ABO2102, which simultaneously covers multiple KRAS mutations, submitted an Investigational New Drug (IND) application (acceptance number:CXSL2500388) has obtained clinical tacit approval.

As the first therapeutic tumor vaccine in China targeting multiple KRAS mutations, ABO2102 is applicable to patients with solid tumors carrying any of the five common KRAS mutations. It represents a significant advancement in the highly challenging field of difficult-to-drug targets.

ABO2102 Receives FDA Approval for Clinical Trials in May and Achieves a Significant Milestone with Dual Approvals in China and the U.S., Demonstrating Abogen's Leading Innovation and Global Strategy in Tumor Immunotherapy.

About KRAS Mutation

KRAS mutation is one of the most common oncogenic gene mutations in solid tumors, often associated with malignant tumors: the incidence of KRAS mutation is as high as about 85% in pancreatic cancer, approximately 40% in colorectal cancer, and around 30% in non-small cell lung cancer. However, since its discovery in 1982, KRAS has long been considered an "undruggable" target due to its relatively smooth protein surface and other unique properties, such as the lack of a "pocket" for drug binding.

Despite recent breakthroughs in KRAS G12C small-molecule inhibitors, limitations such as target specificity, inevitable drug resistance, and limited survival benefits remain unresolved. There is a significant unmet clinical need in the treatment of KRAS-mutant tumors.

Industry data show that in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC),Patients carrying these five common mutations account for a generally high proportion of KRAS-mutated patients, approximately 75%-85%.

This further highlights the urgency and clinical value of developing broad-spectrum KRAS-targeted therapies.

About ABO2102

ABO2102, a therapeutic cancer vaccine developed by Abogen based on its self-innovated mRNA technology platform, has demonstrated excellent anti-tumor activity in preclinical studies through multi-dimensional technological breakthroughs and achieved broad coverage of HLA (Human Leukocyte Antigen) subtypes. This vaccine provides a novel solution for the treatment of KRAS-mutant solid tumors, showcasing strong clinical transformation potential.

1. Multi-target Antigen Design

ABO2102 is an mRNA molecule that simultaneously encodes five common KRAS mutant antigens. After being translated into antigens within the cell, it is presented via MHC-I/II molecules, activating a dual immune response of CD8⁺ cytotoxic T cells and CD4⁺ helper T cells, enabling precise recognition and attack of KRAS mutant antigens. Compared to small-molecule inhibitors that only target the G12C mutation, ABO2102 covers a broader range of KRAS mutation types.

2. Breakthrough in Drug Resistance Dilemma

Due to the single target and the difficulty in addressing the adaptive evolution of the tumor microenvironment, traditional KRAS G12C inhibitors have limited efficacy, with patients typically experiencing a median PFS (Progression Free Survival) of only 6-9 months. In contrast, ABO2102 can induce sustained expansion of specific T cells and establish long-term immune memory.

Preclinical data show that vaccine-activated T cells can precisely recognize neoantigens on the surface of KRAS-mutated cells and effectively kill tumor cells. This endogenous immune response not only avoids the common off-target toxicity of targeted drugs but also continuously suppresses tumor recurrence through immune memory mechanisms. Additionally, studies in mouse models demonstrate that ABO2102, in combination with PD-1 antibodies, has a synergistic effect, further enhancing anti-tumor efficacy.

3. Platform Empowering Drug Development

The development of ABO2102 is based on Abogen's mature tumor vaccine technology platform. First, the vaccine uses an LNP delivery system that has undergone large-scale clinical validation during the COVID-19 period, ensuring efficient mRNA delivery within cells and excellent safety. Second, the platform has modular antigen design capabilities, allowing flexible insertion of different KRAS mutant antigen epitopes to quickly address various mutation types. It also employs next-generation mRNA sequence design, significantly enhancing immunogenicity. Meanwhile, the platform utilizes bioinformatics to predict and select high-coverage antigen epitopes, which have been confirmed through preclinical experiments to demonstrate broad HLA coverage potential.

4. Promising Clinical Translation Prospects

ABO2102 Has the Potential to Shift the Paradigm of KRAS-Targeted Therapy from "Passive Inhibition" to "Active Immune Clearance," Demonstrating Breakthrough Clinical Value. This vaccine, based on a multi-epitope antigen design, precisely covers high-incidence cancer types such as pancreatic cancer, non-small cell lung cancer, and colorectal cancer. Its modular technology platform further supports rapid expansion to other mutation-related indications. With its off-the-shelf advantage, ABO2102 can be used for salvage treatment in advanced patients as well as an adjuvant therapy post-surgery in early-stage cases. Meanwhile, thanks to its excellent safety profile, this vaccine can be combined with chemotherapy, radiotherapy, or immune checkpoint inhibitors, establishing a multi-dimensional synergistic tumor treatment system.

ABO2102 Successfully Achieves Dual Filing and Approval in China and the U.S., Marking a Significant Milestone in Gaining Recognition from Global Regulatory Systems. This Further Demonstrates Abogen's Innovative Strength and International Competitiveness in mRNA Drug Development. In the Future, as Clinical Research Progresses, ABO2102 is Expected to Bring Breakthrough Treatment Options to Patients with KRAS Mutation-Related Tumors, Reshaping the Landscape of Tumor Immunotherapy.

About Us

Abogen Biosciences (referred to as "Abogen") is an innovative biopharmaceutical company focused on the research and development of messenger ribonucleic acid (mRNA) drugs. The company owns industry-leading, proprietary intellectual property rights in mRNA and nanodelivery technology platforms. It is one of the few mRNA drug research and development enterprises in China with complete value chain capabilities, covering all aspects from mRNA design, formulation development to large-scale production. The company has established a rich product pipeline, spanning multiple fields including cancer immunotherapy, autoimmune diseases, and infectious disease prevention and treatment.